Fenoterol hydrobromide
Based on 1 Customer Validation
Fenoterol hydrobromide (Th-1165a), a sympathomimetic agent, is a selective and orally active β2-adrenoceptor agonist. Fenoterol hydrobromide is an effective bronchodilator and can be used for bronchospasm associated with asthma, bronchitis and other obstructive airway diseases research.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 1944-12-3
- Formula: C17H22BrNO4
- Molecular Weight:384.26
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Exosomes Compound Library
HY-L072
-
Anti-Obesity Compound Library
HY-L087
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
All Adrenergic Receptor Isoforms
More
Biological Activity
|
β adrenergic receptor |
Fenoterol (1 μM; pre-incubated 30 minutes) treatment reduces AICAR-induced AMPK activation, NF-κB activation and TNF-α release, and also significantly downregulates the elevated phosphorylation levels of AMPK[2].
?
Fenoterol inhibits lipopolysaccharide (LPS)-induced AMPK activation and inflammatory cytokine production in THP-1 cells[2].
?
Fenoterol is also a potent exosome biogenesis and/or secretion activator in PC cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:THP-1 cells stimulated with AICAR
-
Concentration:1 μM
-
Incubation Time:Pre-incubated 30 minutes
-
Result:Significantly downregulated the elevated phosphorylation levels of AMPK.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6J mice (6 weeks old) with neuropathy[3]
-
Dosage:0.7 mg/kg
-
Administration:Intraperitoneal injection; twice a day; for 3 weeks
-
Result:Alleviated neuropathic allodynia during chronic treatment.
Chemical Information
-
CAS No. 1944-12-3
-
Appearance Solid
-
Molecular Weight 384.26
-
Formula C17H22BrNO4
-
Color White to off-white
-
SMILES
[H]Br.OC1=CC(C(O)CNC(C)CC2=CC=C(O)C=C2)=CC(O)=C1
-
Synonyms
Th-1165a; Phenoterol hydrobromide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 100 mg/mL (260.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (65.06 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 60 mg/mL (156.14 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. R C Heel, et al. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs. 1978 Jan;15(1):3-32. [Content Brief]
[2]. Wei Wang, et al. Anti-inflammatory activities of fenoterol through β-arrestin-2 and inhibition of AMPK and NF-κB activation in AICAR-induced THP-1 cells. Biomed Pharmacother. 2016 Dec;84:185-190. [Content Brief]
[3]. Nada Choucair-Jaafar, et al. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br J Pharmacol. 2009 Dec;158(7):1683-94. [Content Brief]
[4]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.6024 mL | 13.0120 mL | 26.0240 mL | 65.0601 mL |
| 5 mM | 0.5205 mL | 2.6024 mL | 5.2048 mL | 13.0120 mL | |
| 10 mM | 0.2602 mL | 1.3012 mL | 2.6024 mL | 6.5060 mL | |
| 15 mM | 0.1735 mL | 0.8675 mL | 1.7349 mL | 4.3373 mL | |
| 20 mM | 0.1301 mL | 0.6506 mL | 1.3012 mL | 3.2530 mL | |
| 25 mM | 0.1041 mL | 0.5205 mL | 1.0410 mL | 2.6024 mL | |
| 30 mM | 0.0867 mL | 0.4337 mL | 0.8675 mL | 2.1687 mL | |
| 40 mM | 0.0651 mL | 0.3253 mL | 0.6506 mL | 1.6265 mL | |
| 50 mM | 0.0520 mL | 0.2602 mL | 0.5205 mL | 1.3012 mL | |
| 60 mM | 0.0434 mL | 0.2169 mL | 0.4337 mL | 1.0843 mL | |
| DMSO | 80 mM | 0.0325 mL | 0.1627 mL | 0.3253 mL | 0.8133 mL |
| 100 mM | 0.0260 mL | 0.1301 mL | 0.2602 mL | 0.6506 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz